Anti-SLAMF8 monoclonal antibody

Pre-made anti-SLAMF8 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SLAMF8/SLAMF8 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1641-Ab-1/ GM-Tg-hg-IP1641-Ab-2Anti-Human SLAMF8 monoclonal antibodyHuman
GM-Tg-rg-IP1641-Ab-1/ GM-Tg-rg-IP1641-Ab-2Anti-Rat SLAMF8 monoclonal antibodyRat
GM-Tg-mg-IP1641-Ab-1/ GM-Tg-mg-IP1641-Ab-2Anti-Mouse SLAMF8 monoclonal antibodyMouse
GM-Tg-cynog-IP1641-Ab-1/ GM-Tg-cynog-IP1641-Ab-2Anti-Cynomolgus/ Rhesus macaque SLAMF8 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1641-Ab-1/ GM-Tg-felg-IP1641-Ab-2Anti-Feline SLAMF8 monoclonal antibodyFeline
GM-Tg-cang-IP1641-Ab-1/ GM-Tg-cang-IP1641-Ab-2Anti-Canine SLAMF8 monoclonal antibodyCanine
GM-Tg-bovg-IP1641-Ab-1/ GM-Tg-bovg-IP1641-Ab-2Anti-Bovine SLAMF8 monoclonal antibodyBovine
GM-Tg-equg-IP1641-Ab-1/ GM-Tg-equg-IP1641-Ab-2Anti-Equine SLAMF8 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1641-Ab-1/ GM-Tg-hg-IP1641-Ab-2; GM-Tg-rg-IP1641-Ab-1/ GM-Tg-rg-IP1641-Ab-2;
GM-Tg-mg-IP1641-Ab-1/ GM-Tg-mg-IP1641-Ab-2; GM-Tg-cynog-IP1641-Ab-1/ GM-Tg-cynog-IP1641-Ab-2;
GM-Tg-felg-IP1641-Ab-1/ GM-Tg-felg-IP1641-Ab-2; GM-Tg-cang-IP1641-Ab-1/ GM-Tg-cang-IP1641-Ab-2;
GM-Tg-bovg-IP1641-Ab-1/ GM-Tg-bovg-IP1641-Ab-2; GM-Tg-equg-IP1641-Ab-1/ GM-Tg-equg-IP1641-Ab-2
Products NameAnti-SLAMF8 monoclonal antibody
Formatmab
Target NameSLAMF8
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SLAMF8 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1641-Ag-1Recombinant multi-species SLAF8/ SLAMF8/ BLAME protein


    Target information

    Target IDGM-IP1641
    Target NameSLAMF8
    Gene ID56833,74748,289237,719494,488631,101092332,514609,100057842
    Gene Symbol and Synonyms5830408F06Rik,BLAME,CD353,SBBI42,SLAMF8
    Uniprot AccessionQ9P0V8
    Uniprot Entry NameSLAF8_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseOvary Cancer
    Gene EnsemblENSG00000158714
    Target ClassificationN/A

    The target: SLAMF8, gene name: SLAMF8, also named as BLAME, CD353, SBBI42. This gene encodes a member of the CD2 family of cell surface proteins involved in lymphocyte activation. These proteins are characterized by Ig domains. This protein is expressed in lymphoid tissues, and studies of a similar protein in mouse suggest that it may function during B cell lineage commitment. The gene is found in a region of chromosome 1 containing many CD2 genes. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.